Home > Insider Trading > Filing (0001567619-19-009908)

Filing Details

Accession Number:: 0001567619-19-009908
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-05-06 18:01:23
Reporting Period:: 2019-05-03

Accepted Time:: 2019-05-06 18:01:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1219445	P Brian Mckeon	One Idexx Drive Westbrook ME 04092	Executive Vp & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-05-03	7,504	$44.05	55,032	No	4	M	Direct
Common Stock	Disposition	2019-05-03	204	$242.72	54,828	No	4	S	Direct
Common Stock	Disposition	2019-05-03	300	$244.57	54,528	No	4	S	Direct
Common Stock	Disposition	2019-05-03	375	$245.77	54,153	No	4	S	Direct
Common Stock	Disposition	2019-05-03	225	$247.28	53,928	No	4	S	Direct
Common Stock	Disposition	2019-05-03	5,771	$248.28	48,157	No	4	S	Direct
Common Stock	Disposition	2019-05-03	629	$248.79	47,528	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right-to-buy)	Disposition	2019-05-03	7,504	$0.00	7,504	$44.05

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2019-05-08	No	4	M	Direct

Footnotes

Includes 32 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 29, 2019.
Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person.
Represents the weighted average price of the shares sold ranging from a low of $242.42 to a high of $243.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $244.00 to a high of $244.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $245.35 to a high of $246.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $246.61 to a high of $247.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $247.745 to a high of $247.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $248.765 to a high of $248.8475 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Grant of option to buy 3,752 shares of IDEXX Laboratories, Inc. common stock that became exercisable one installment on May 9, 2013 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Not applicable.